Related references
Note: Only part of the references are listed.Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men
Paola Russo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Genetic variation in two proteins of the endocannabinoid system and their influence on body mass index and metabolism under low fat diet
J. Aberle et al.
HORMONE AND METABOLIC RESEARCH (2007)
No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents
Timo Dirk Mueller et al.
MOLECULAR GENETICS AND METABOLISM (2007)
The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men
Armand Peeters et al.
ENDOCRINE (2007)
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Andre J. Scheen et al.
LANCET (2006)
The PPARG pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism -: The Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study
R Jaziri et al.
DIABETES (2006)
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: A randomized controlled trial
F Pi-Sunyer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
JP Despres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Lack of CB1 cannabinoid receptor impairs cocaine self-administration
G Soria et al.
NEUROPSYCHOPHARMACOLOGY (2005)
Cholesterol-dependent modulation of type 1 cannabinoid receptors in nerve cells
M Bari et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2005)
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:: 1-year experience from the RIO-Europe study
LF Van Gaal et al.
LANCET (2005)
The endocannabinoid system and the treatment of obesity
U Pagotto et al.
ANNALS OF MEDICINE (2005)
Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix
J Li et al.
HEREDITY (2005)
CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity
CR Trillou et al.
INTERNATIONAL JOURNAL OF OBESITY (2004)
A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other
DR Nyholt
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Human cannabinoid receptor 1:: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse
PW Zhang et al.
MOLECULAR PSYCHIATRY (2004)
Pedigree disequilibrium tests for multilocus haplotypes
F Dudbridge
GENETIC EPIDEMIOLOGY (2003)
Binge eating as a major phenotype of melanocortin 4 receptor gene mutations
R Branson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice
CR Trillou et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2003)
Exact inference for categorical data: recent advances and continuing controversies
A Agresti
STATISTICS IN MEDICINE (2001)
Leptin-regulated endocannabinoids are involved in maintaining food intake
V Di Marzo et al.
NATURE (2001)
Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol
CJ Hillard
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2000)
Share Paper
